Clinical trials: Diphosphonates
Neuroblastoma
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor in children, with an annual incidence of 10.5 per million children less than 15 years of age. NB accounts for 15% of childhood cancer deaths.
- Trial name
- NCT01404702
- Testing
- Zoledronic Acid, Aldesleukin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Osteogenesis Imperfecta
Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab
Pilot study to assess the efficacy of a therapy with the RANKL-antibody denosumab in children 5-10 years of age with mutation in COL1A1 or COL1A2 leading to Osteogenesis imperfecta.
- Trial name
- OI-AK (NCT01799798)
- Testing
- Denosumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Cologne
Osteogenesis Imperfecta, Osteoporosis
Bisphosphonate Therapy for Osteogenesis Imperfecta
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)." We, the researchers at Indiana University School of Medicine, are characterizing the changes effected by oral…
- Conditions
- Osteogenesis Imperfecta, Osteoporosis, Paget Disease of Bone
- Trial name
- NCT00159419
- Testing
- Alendronate, Pamidronate
- Volunteers
- 18 people
- Sponsor
- Indiana University
Osteogenesis Imperfecta
Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?
Osteogenesis Imperfecta(OI) is an inherited disorder characterised by extreme fragility of the bones. Bones often break from little or no apparent cause.
- Trial name
- BAMES (NCT03208582)
- Testing
- Risedronate Sodium, Calcichew tablets
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Sheffield Children's NHS Foundation Trust
Osteoporosis
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- Trial name
- NCT00520052
- Testing
- zoledronic acid
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust